CareDx Announced Medicare Reimbursement Pricing of $2,753 for AlloSure Heart
CareDx, Inc. (Nasdaq: CDNA) announced it has received final reimbursement pricing of $2,753 from Palmetto MolDx for AlloSure Heart.
· 11/17/2020 05:28
CareDx, Inc. (NASDAQ:CDNA) announced it has received final reimbursement pricing of $2,753 from Palmetto MolDx for AlloSure Heart. AlloSure Heart is a donor-derived cell-free DNA (dd-cfDNA) test which can identify underlying cell injury leading to organ rejection, and is covered by Medicare when used in conjunction with AlloMap Heart gene expression profiling. HeartCare, the combination of AlloSure Heart and AlloMap Heart, provides a multi-modality and non-invasive solution for managing the care of transplant patients. "We are pleased to reach this milestone for AlloSure Heart which broadens accessibility to HeartCare, and improves management of heart transplant patients," said Reg Seeto, President and Chief Executive Officer. "This non-invasive, multi-modality solution represents the latest innovation in precision medicine. HeartCare will help redefine the way clinicians manage the care of transplant patients."